Prophylactic effect of ensitrelvir in mice infected with SARS-CoV-2
Haruaki Nobori, Keiko Baba, Takayuki Kuroda, Kaoru Baba, Kazumi Matsumoto, Shinpei Yoshida, Ryosuke Watari, Yuki Tachibana, Teruhisa Kato, Keita Fukao
Antiviral Research, doi:10.1016/j.antiviral.2024.105852
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the etiological cause of coronavirus disease 2019 and continues to be a major health concern worldwide. Strategies to protect individuals at high risk of COVID-19 are critical but are currently a largely unmet need. We evaluated the oral antiviral drug ensitrelvir, which specifically targets the SARS-CoV-2 3CL protease, for its efficacy as a pre-exposure prophylactic treatment. Aged BALB/c mice were subcutaneously treated with various doses of ensitrelvir 24 h prior to a lethal SARS-CoV-2 challenge infection. Mouse body weight changes, survival rates, and viral titers in the lungs were evaluated, and plasma concentrations of ensitrelvir were determined. A single subcutaneous administration of ensitrelvir at 64 mg/kg or greater 24 h prior to SARS-CoV-2 challenge infection significantly protected aged mice against lethality and inhibited body weight loss. Pharmacokinetic analysis of ensitrelvir in the aged mice suggested that plasma concentrations ≥ 2.99 µg/mL resulted in a significant prophylactic effect against SARS-CoV-2 infection. In the aged mouse prophylaxis model, SARS-CoV-2 titers were suppressed in the lungs of mice treated with ensitrelvir 24 h prior to challenge infection, suggesting that the prophylactic administration of ensitrelvir exerted its prophylactic effect by suppressing viral proliferation. These findings suggest that ensitrelvir is a candidate drug for pre-exposure prophylactic treatment of individuals at high risk of COVID-19.
Effect of prophylactic ensitrelvir on body weight in aged mice infected with SARS-CoV-2 The prophylactic effect of S-217622 against lethal infection with the SARS-CoV-2 MA-P10 strain in mice was evaluated by monitoring body weight loss for 14 d post-challenge infection. A single dose of ensitrelvir administered subcutaneously at 64, 96, or 128 mg/kg 24 h prior to infection significantly suppressed body weight loss due to SARS-CoV-2 infection (Fig. 3 and Supplementary Figure S2 ). A single subcutaneous dose of 32 mg/kg ensitrelvir failed to provide significant prophylactic protection compared to that of vehicle (P ≥ 0.3039). The 64 mg/kg and 96 mg/kg ensitrelvir treatment provided significant protection from weight loss compared to that of vehicle from day 3 through day 7 post-infection (P < 0.05 -P < 0.001). Significant protection was also observed for ensitrelvir doses 128 mg/kg from day 2 through day 7 post-infection (P < 0.001).
Effect of prophylactic ensitrelvir on viral load in the lungs of aged mice infected with SARS-
CoV-2 To evaluate the prophylactic effect of ensitrelvir against lethal infection with the SARS-CoV-2 MA-P10 strain, lung virus titers were measured at 1, 2, 4, and 9 d post-challenge infection. A single prophylactic subcutaneous administration of 64 or 128 mg/kg ensitrelvir 24 h before infection significantly suppressed the lung viral load in mice (Fig. 4 , Supplementary Table S1 ). The lung viral titers peaked at 2 d post-infection and..
References
Alpizar, Accini, Anderson, Eysa, Medina-Piñón et al., Molnupiravir for intra-household prevention of COVID-19: The MOVe-AHEAD randomized, placebo-controlled trial, J. Infect,
doi:10.1016/j.jinf.2023.08.016Ando, Noshi, Sato, Ishibashi, Yoshida et al., Pharmacokinetic and pharmacodynamic analysis of baloxavir marboxil, a novel cap-dependent endonuclease inhibitor, in a murine model of influenza virus infection, J. Antimicrob. Chemother,
doi:10.1093/jac/dkaa393Fukao, Nobori, Kuroda, Baba, Matsumoto et al., Pharmacokinetic and pharmacodynamic analysis of the 3CL protease inhibitor ensitrelvir in a SARS-CoV-2 infection mouse model, Viruses,
doi:10.3390/v15102052Hayden, Gubareva, Monto, Klein, Elliot et al., Inhaled zanamivir for the prevention of influenza in families. Zanamivir Family Study Group, N. Engl. J. Med,
doi:10.1056/NEJM200011023431801Ikematsu, Hayden, Kawaguchi, Kinoshita, De Jong et al., Baloxavir marboxil for prophylaxis against influenza in household contacts, N. Engl. J. Med,
doi:10.1056/NEJMoa1915341Kashiwagi, Watanabe, Ikematsu, Awamura, Okamoto et al., Laninamivir octanoate for post-exposure prophylaxis of influenza in household contacts: a randomized double blind placebo controlled trial, J. Infect. Chemother,
doi:10.1007/s10156-013-0622-9Kawashima, Matsui, Adachi, Morikawa, Inoue et al., Ensitrelvir is effective against SARS-CoV-2 3CL protease mutants circulating globally, Biochem. Biophys. Res. Commun,
doi:10.1016/j.bbrc.2023.01.040Kuroda, Nobori, Fukao, Baba, Matsumoto et al., Efficacy comparison of 3CL protease inhibitors ensitrelvir and nirmatrelvir against SARS-CoV-2 in vitro and in vivo, J. Antimicrob. Chemother,
doi:10.1093/jac/dkad027Martins-Filho, Ferreira, Heimfarth, De Souza Araújo, Quintans-Júnior, Efficacy and safety of hydroxychloroquine as pre-and post-exposure prophylaxis and J o u r n a l P r e -p r o o f treatment of COVID-19: A systematic review and meta-analysis of blinded, placebocontrolled, randomized clinical trials, Lancet Reg. Health Am,
doi:10.1016/j.lana.2021.100062Matsuyama, Nao, Shirato, Kawase, Saito et al., Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing cells, Proc. Natl. Acad. Sci. U. S. A,
doi:10.1073/pnas.2002589117Mukae, Yotsuyanagi, Ohmagari, Doi, Imamura et al., A randomized phase 2/3 study of ensitrelvir, a novel oral SARS-CoV-2 3C-like protease inhibitor, in Japanese patients with mild-to-moderate COVID-19 or asymptomatic SARS-CoV-2 infection: results of the phase 2a part, Antimicrob. Agents Chemother,
doi:10.1128/aac.00697-22Mukae, Yotsuyanagi, Ohmagari, Doi, Sakaguchi et al., Efficacy and safety of ensitrelvir in patients with mild-to-moderate COVID-19: the phase 2b part of a randomized, placebocontrolled, phase 2/3 study, Clin. Infect. Dis,
doi:10.1101/2022.06.22.22276792Nobori, Fukao, Kuroda, Anan, Tashima et al., Efficacy of ensitrelvir against SARS-CoV-2 in a delayed-treatment mouse model, J. Antimicrob. Chemother,
doi:10.1093/jac/dkac257Ouyang, Zaongo, Harypursat, Li, Routy et al., SARS-CoV-2 pre-exposure prophylaxis: A potential COVID-19 preventive strategy for high-risk populations, including healthcare workers, immunodeficient individuals, and poor vaccine responders, Front. Public Health,
doi:10.3389/fpubh.2022.945448Pfizer, Pfizer Shares Top-Line Results from Phase 2/3 EPIC-PEP Study of PAXLOVID™ for Post-Exposure Prophylactic Use
Shimizu, Sonoyama, Fukuhara, Kuwata, Matsuo et al., A phase 1 study of ensitrelvir fumaric acid tablets evaluating the safety, pharmacokinetics and food effect in healthy adult populations, Clin. Drug Investig,
doi:10.1007/s40261-023-01309-zUemura, Nobori, Sato, Toba, Kusakabe et al., 2-Thiouridine is a broad-spectrum antiviral nucleoside analogue against positive-strand RNA viruses, Proc. Natl. Acad. Sci. U. S. A,
doi:10.1073/pnas.2304139120Unoh, Uehara, Nakahara, Nobori, Yamatsu et al., Discovery of S-217622, a Noncovalent Oral SARS-J o u r n a l P r e -p r o o f CoV-2 3CL Protease Inhibitor Clinical Candidate for Treating COVID-19, J. Med. Chem,
doi:10.1021/acs.jmedchem.2c00117Vangeel, Chiu, De Jonghe, Maes, Slechten et al., Remdesivir, molnupiravir and nirmatrelvir remain active against SARS-CoV-2 Omicron and other variants of concern, Antiviral Res,
doi:10.1016/j.antiviral.2022.105252Welliver, Monto, Carewicz, Schatteman, Hassman et al., Effectiveness of oseltamivir in preventing influenza in household contacts: a randomized controlled trial,
doi:10.1001/jama.285.6.748DOI record:
{
"DOI": "10.1016/j.antiviral.2024.105852",
"ISSN": [
"0166-3542"
],
"URL": "http://dx.doi.org/10.1016/j.antiviral.2024.105852",
"alternative-id": [
"S0166354224000603"
],
"article-number": "105852",
"assertion": [
{
"label": "This article is maintained by",
"name": "publisher",
"value": "Elsevier"
},
{
"label": "Article Title",
"name": "articletitle",
"value": "Prophylactic effect of ensitrelvir in mice infected with SARS-CoV-2"
},
{
"label": "Journal Title",
"name": "journaltitle",
"value": "Antiviral Research"
},
{
"label": "CrossRef DOI link to publisher maintained version",
"name": "articlelink",
"value": "https://doi.org/10.1016/j.antiviral.2024.105852"
},
{
"label": "Content Type",
"name": "content_type",
"value": "article"
},
{
"label": "Copyright",
"name": "copyright",
"value": "© 2024 The Authors. Published by Elsevier B.V."
}
],
"author": [
{
"affiliation": [],
"family": "Nobori",
"given": "Haruaki",
"sequence": "first"
},
{
"affiliation": [],
"family": "Baba",
"given": "Keiko",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Kuroda",
"given": "Takayuki",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Baba",
"given": "Kaoru",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Matsumoto",
"given": "Kazumi",
"sequence": "additional"
},
{
"ORCID": "http://orcid.org/0000-0002-0004-5845",
"affiliation": [],
"authenticated-orcid": false,
"family": "Yoshida",
"given": "Shinpei",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Watari",
"given": "Ryosuke",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Tachibana",
"given": "Yuki",
"sequence": "additional"
},
{
"ORCID": "http://orcid.org/0000-0001-5041-0110",
"affiliation": [],
"authenticated-orcid": false,
"family": "Kato",
"given": "Teruhisa",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Fukao",
"given": "Keita",
"sequence": "additional"
}
],
"container-title": "Antiviral Research",
"container-title-short": "Antiviral Research",
"content-domain": {
"crossmark-restriction": true,
"domain": [
"elsevier.com",
"sciencedirect.com"
]
},
"created": {
"date-parts": [
[
2024,
2,
28
]
],
"date-time": "2024-02-28T10:55:24Z",
"timestamp": 1709117724000
},
"deposited": {
"date-parts": [
[
2024,
2,
29
]
],
"date-time": "2024-02-29T16:28:24Z",
"timestamp": 1709224104000
},
"indexed": {
"date-parts": [
[
2024,
3,
1
]
],
"date-time": "2024-03-01T00:44:11Z",
"timestamp": 1709253851517
},
"is-referenced-by-count": 0,
"issued": {
"date-parts": [
[
2024,
2
]
]
},
"language": "en",
"license": [
{
"URL": "https://www.elsevier.com/tdm/userlicense/1.0/",
"content-version": "tdm",
"delay-in-days": 0,
"start": {
"date-parts": [
[
2024,
2,
1
]
],
"date-time": "2024-02-01T00:00:00Z",
"timestamp": 1706745600000
}
},
{
"URL": "http://creativecommons.org/licenses/by-nc-nd/4.0/",
"content-version": "vor",
"delay-in-days": 28,
"start": {
"date-parts": [
[
2024,
2,
29
]
],
"date-time": "2024-02-29T00:00:00Z",
"timestamp": 1709164800000
}
}
],
"link": [
{
"URL": "https://api.elsevier.com/content/article/PII:S0166354224000603?httpAccept=text/xml",
"content-type": "text/xml",
"content-version": "vor",
"intended-application": "text-mining"
},
{
"URL": "https://api.elsevier.com/content/article/PII:S0166354224000603?httpAccept=text/plain",
"content-type": "text/plain",
"content-version": "vor",
"intended-application": "text-mining"
}
],
"member": "78",
"original-title": [],
"page": "105852",
"prefix": "10.1016",
"published": {
"date-parts": [
[
2024,
2
]
]
},
"published-print": {
"date-parts": [
[
2024,
2
]
]
},
"publisher": "Elsevier BV",
"reference": [
{
"DOI": "10.1016/j.jinf.2023.08.016",
"article-title": "Molnupiravir for intra-household prevention of COVID-19: the MOVe-AHEAD randomized, placebo-controlled trial",
"author": "Alpizar",
"doi-asserted-by": "crossref",
"first-page": "392",
"journal-title": "J. Infect.",
"key": "10.1016/j.antiviral.2024.105852_bib1",
"volume": "87",
"year": "2023"
},
{
"DOI": "10.1093/jac/dkaa393",
"article-title": "Pharmacokinetic and pharmacodynamic analysis of baloxavir marboxil, a novel cap-dependent endonuclease inhibitor, in a murine model of influenza virus infection",
"author": "Ando",
"doi-asserted-by": "crossref",
"first-page": "189",
"journal-title": "J. Antimicrob. Chemother.",
"key": "10.1016/j.antiviral.2024.105852_bib2",
"volume": "76",
"year": "2021"
},
{
"DOI": "10.3390/v15102052",
"article-title": "Pharmacokinetic and pharmacodynamic analysis of the 3CL protease inhibitor ensitrelvir in a SARS-CoV-2 infection mouse model",
"author": "Fukao",
"doi-asserted-by": "crossref",
"first-page": "2052",
"journal-title": "Viruses",
"key": "10.1016/j.antiviral.2024.105852_bib3",
"volume": "15",
"year": "2023"
},
{
"DOI": "10.1016/j.it.2020.10.004",
"article-title": "Mechanisms of SARS-CoV-2 transmission and pathogenesis",
"author": "Harrison",
"doi-asserted-by": "crossref",
"first-page": "1100",
"journal-title": "Trends Immunol.",
"key": "10.1016/j.antiviral.2024.105852_bib4",
"volume": "41",
"year": "2020"
},
{
"DOI": "10.1056/NEJM200011023431801",
"article-title": "Inhaled zanamivir for the prevention of influenza in families. Zanamivir Family Study Group",
"author": "Hayden",
"doi-asserted-by": "crossref",
"first-page": "1282",
"journal-title": "N. Engl. J. Med.",
"key": "10.1016/j.antiviral.2024.105852_bib5",
"volume": "343",
"year": "2000"
},
{
"DOI": "10.1056/NEJMoa1915341",
"article-title": "Baloxavir marboxil for prophylaxis against influenza in household contacts",
"author": "Ikematsu",
"doi-asserted-by": "crossref",
"first-page": "309",
"journal-title": "N. Engl. J. Med.",
"key": "10.1016/j.antiviral.2024.105852_bib6",
"volume": "383",
"year": "2020"
},
{
"DOI": "10.1007/s10156-013-0622-9",
"article-title": "Laninamivir octanoate for post-exposure prophylaxis of influenza in household contacts: a randomized double blind placebo controlled trial",
"author": "Kashiwagi",
"doi-asserted-by": "crossref",
"first-page": "740",
"journal-title": "J. Infect. Chemother.",
"key": "10.1016/j.antiviral.2024.105852_bib7",
"volume": "19",
"year": "2013"
},
{
"DOI": "10.1016/j.bbrc.2023.01.040",
"article-title": "Ensitrelvir is effective against SARS-CoV-2 3CL protease mutants circulating globally",
"author": "Kawashima",
"doi-asserted-by": "crossref",
"first-page": "132",
"journal-title": "Biochem. Biophys. Res. Commun.",
"key": "10.1016/j.antiviral.2024.105852_bib8",
"volume": "645",
"year": "2023"
},
{
"DOI": "10.1093/jac/dkad027",
"article-title": "Efficacy comparison of 3CL protease inhibitors ensitrelvir and nirmatrelvir against SARS-CoV-2 in vitro and in vivo",
"author": "Kuroda",
"doi-asserted-by": "crossref",
"first-page": "946",
"journal-title": "J. Antimicrob. Chemother.",
"key": "10.1016/j.antiviral.2024.105852_bib9",
"volume": "78",
"year": "2023"
},
{
"article-title": "Efficacy and safety of hydroxychloroquine as pre-and post-exposure prophylaxis and treatment of COVID-19: a systematic review and meta-analysis of blinded, placebo-controlled, randomized clinical trials",
"author": "Martins-Filho",
"journal-title": "Lancet Reg. Health Am.",
"key": "10.1016/j.antiviral.2024.105852_bib10",
"volume": "2",
"year": "2021"
},
{
"DOI": "10.1073/pnas.2002589117",
"article-title": "Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing cells",
"author": "Matsuyama",
"doi-asserted-by": "crossref",
"first-page": "7001",
"journal-title": "Proc. Natl. Acad. Sci. U. S. A.",
"key": "10.1016/j.antiviral.2024.105852_bib11",
"volume": "117",
"year": "2020"
},
{
"DOI": "10.1128/aac.00697-22",
"article-title": "A randomized phase 2/3 study of ensitrelvir, a novel oral SARS-CoV-2 3C-like protease inhibitor, in Japanese patients with mild-to-moderate COVID-19 or asymptomatic SARS-CoV-2 infection: results of the phase 2a part",
"author": "Mukae",
"doi-asserted-by": "crossref",
"journal-title": "Antimicrob. Agents Chemother.",
"key": "10.1016/j.antiviral.2024.105852_bib12",
"volume": "66",
"year": "2022"
},
{
"DOI": "10.1093/cid/ciac933",
"article-title": "Efficacy and safety of ensitrelvir in patients with mild-to-moderate COVID-19: the phase 2b part of a randomized, placebo-controlled, phase 2/3 study",
"author": "Mukae",
"doi-asserted-by": "crossref",
"first-page": "1403",
"journal-title": "Clin. Infect. Dis.",
"key": "10.1016/j.antiviral.2024.105852_bib13",
"volume": "76",
"year": "2022"
},
{
"DOI": "10.1093/jac/dkac257",
"article-title": "Efficacy of ensitrelvir against SARS-CoV-2 in a delayed-treatment mouse model",
"author": "Nobori",
"doi-asserted-by": "crossref",
"first-page": "2984",
"journal-title": "J. Antimicrob. Chemother.",
"key": "10.1016/j.antiviral.2024.105852_bib14",
"volume": "77",
"year": "2022"
},
{
"DOI": "10.3389/fpubh.2022.945448",
"article-title": "SARS-CoV-2 pre-exposure prophylaxis: a potential COVID-19 preventive strategy for high-risk populations, including healthcare workers, immunodeficient individuals, and poor vaccine responders",
"author": "Ouyang",
"doi-asserted-by": "crossref",
"journal-title": "Front. Public Health",
"key": "10.1016/j.antiviral.2024.105852_bib15",
"volume": "10",
"year": "2022"
},
{
"author": "Pfizer",
"key": "10.1016/j.antiviral.2024.105852_bib16",
"series-title": "Pfizer Shares Top-Line Results from Phase 2/3 EPIC-PEP Study of PAXLOVID™ for Post-Exposure Prophylactic Use",
"year": "2022"
},
{
"DOI": "10.1007/s40261-023-01309-z",
"article-title": "A phase 1 study of ensitrelvir fumaric acid tablets evaluating the safety, pharmacokinetics and food effect in healthy adult populations",
"author": "Shimizu",
"doi-asserted-by": "crossref",
"first-page": "785",
"journal-title": "Clin. Drug Invest.",
"key": "10.1016/j.antiviral.2024.105852_bib17",
"volume": "43",
"year": "2023"
},
{
"DOI": "10.1073/pnas.2304139120",
"article-title": "2-Thiouridine is a broad-spectrum antiviral nucleoside analogue against positive-strand RNA viruses",
"author": "Uemura",
"doi-asserted-by": "crossref",
"journal-title": "Proc. Natl. Acad. Sci. U. S. A.",
"key": "10.1016/j.antiviral.2024.105852_bib18",
"volume": "120",
"year": "2023"
},
{
"DOI": "10.1016/j.bmcl.2020.127377",
"article-title": "The SARS-CoV-2 main protease as drug target",
"author": "Ullrich",
"doi-asserted-by": "crossref",
"journal-title": "Bioorg. Med. Chem. Lett.",
"key": "10.1016/j.antiviral.2024.105852_bib19",
"volume": "30",
"year": "2020"
},
{
"DOI": "10.1021/acs.jmedchem.2c00117",
"article-title": "Discovery of S-217622, a noncovalent oral SARS-CoV-2 3CL protease inhibitor clinical candidate for treating COVID-19",
"author": "Unoh",
"doi-asserted-by": "crossref",
"first-page": "6499",
"journal-title": "J. Med. Chem.",
"key": "10.1016/j.antiviral.2024.105852_bib20",
"volume": "65",
"year": "2022"
},
{
"DOI": "10.1016/j.antiviral.2022.105252",
"article-title": "Remdesivir, molnupiravir and nirmatrelvir remain active against SARS-CoV-2 Omicron and other variants of concern",
"author": "Vangeel",
"doi-asserted-by": "crossref",
"journal-title": "Antivir. Res.",
"key": "10.1016/j.antiviral.2024.105852_bib21",
"volume": "198",
"year": "2022"
},
{
"DOI": "10.1001/jama.285.6.748",
"article-title": "Effectiveness of oseltamivir in preventing influenza in household contacts: a randomized controlled trial",
"author": "Welliver",
"doi-asserted-by": "crossref",
"first-page": "748",
"journal-title": "JAMA",
"key": "10.1016/j.antiviral.2024.105852_bib22",
"volume": "285",
"year": "2001"
},
{
"key": "10.1016/j.antiviral.2024.105852_bib23",
"series-title": "Organization Weekly Epidemiological Update on COVID-19",
"year": "2023"
}
],
"reference-count": 23,
"references-count": 23,
"relation": {},
"resource": {
"primary": {
"URL": "https://linkinghub.elsevier.com/retrieve/pii/S0166354224000603"
}
},
"score": 1,
"short-title": [],
"source": "Crossref",
"subject": [
"Virology",
"Pharmacology"
],
"subtitle": [],
"title": "Prophylactic effect of ensitrelvir in mice infected with SARS-CoV-2",
"type": "journal-article",
"update-policy": "http://dx.doi.org/10.1016/elsevier_cm_policy"
}
